Nykode Therapeutics has announced key conclusions from the updated analysis from the Phase 2 VB-C-02 trial.

The trial investigates the use of Nykode’s wholly-owned off-the-shelf therapeutic cancer vaccine candidate VB10.16 in combination with Roche’s checkpoint inhibitor atezolizumab in patients with recurrent or metastatic HPV16-positive cervical cancer. The updated results, which closely mirror the previously reported positive C-02 outcomes, affirm prolonged benefits and indicate a synergistic treatment effect of VB10.16 plus atezolizumab compared to the historical controls of monotherapy with checkpoint inhibitors. The updated analysis’ observation time for the remaining patients was at least 24 months, compared to at least 12 months at the previously reported outcome.

We are more confident than ever in the transformative potential of Nykode’s immunotherapies.”

“I am thrilled with these data which yet again underscore the strength of our Nykode technology. The strength and durability of the clinical response points to a unique and highly differentiated therapy and we continue our efforts to bring VB10.16 to patients as fast as possible. We are more confident than ever in the transformative potential of Nykode’s immunotherapies,” said Michael Engsig, CEO.

Nykode has a focused strategy to develop VB10.16, including a potentially US registrational trial C-04 in recurrent/metastatic cervical cancer and a C-03 trial in first-line head and neck cancer, two areas with a high unmet medical need. The company is also planning to move VB10.16 into early-stage cervical cancer.

Photo of Michael Engsig: Nykode